Cardiovascular Systems Inc (NASDAQ:CSII) – Equities research analysts at Northcoast Research issued their Q3 2018 earnings per share (EPS) estimates for Cardiovascular Systems in a report released on Thursday. Northcoast Research analyst D. Keiser forecasts that the medical device company will post earnings of ($0.01) per share for the quarter. Northcoast Research also issued estimates for Cardiovascular Systems’ Q4 2018 earnings at $0.04 EPS, FY2018 earnings at ($0.04) EPS, Q1 2019 earnings at $0.03 EPS, Q2 2019 earnings at $0.06 EPS, Q3 2019 earnings at $0.07 EPS, Q4 2019 earnings at $0.12 EPS and FY2019 earnings at $0.28 EPS.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative return on equity of 0.51% and a negative net margin of 1.62%. The firm had revenue of $52.63 million during the quarter, compared to the consensus estimate of $53.39 million. During the same period last year, the business posted $0.03 EPS. The business’s revenue was up 5.2% compared to the same quarter last year.
Shares of Cardiovascular Systems (CSII) opened at $22.40 on Monday. The company has a current ratio of 4.30, a quick ratio of 3.83 and a debt-to-equity ratio of 0.18. Cardiovascular Systems has a 1-year low of $21.03 and a 1-year high of $33.11. The firm has a market capitalization of $741.11, a PE ratio of -224.00 and a beta of 2.32.
Several hedge funds have recently added to or reduced their stakes in CSII. Point72 Asset Management L.P. boosted its position in shares of Cardiovascular Systems by 132.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 469,978 shares of the medical device company’s stock worth $13,230,000 after purchasing an additional 267,988 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Cardiovascular Systems by 12.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,864,604 shares of the medical device company’s stock worth $60,096,000 after purchasing an additional 208,248 shares in the last quarter. Gabelli Funds LLC boosted its position in shares of Cardiovascular Systems by 223.1% during the 3rd quarter. Gabelli Funds LLC now owns 218,500 shares of the medical device company’s stock worth $6,151,000 after purchasing an additional 150,880 shares in the last quarter. Thomson Horstmann & Bryant Inc. bought a new position in shares of Cardiovascular Systems during the 4th quarter worth about $3,463,000. Finally, BlackRock Inc. boosted its position in shares of Cardiovascular Systems by 4.1% during the 4th quarter. BlackRock Inc. now owns 2,265,706 shares of the medical device company’s stock worth $53,676,000 after purchasing an additional 88,999 shares in the last quarter. 75.29% of the stock is currently owned by institutional investors.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.